Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Identifieur interne : 003185 ( PubMed/Corpus ); précédent : 003184; suivant : 003186Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Auteurs : Paul Ruff ; David R. Ferry ; Radek Lakom ; Jana Prausová ; Guy A. Van Hazel ; Paulo M. Hoff ; David Cunningham ; Dirk Arnold ; Hans J. Schmoll ; Vladimir M. Moiseyenko ; Joseph J. Mckendrick ; Albert J. Ten Tije ; Raghu L. Vishwanath ; Pankaj Bhargava ; Soazig Chevalier ; Teresa Macarulla ; Eric Van CutsemSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2015.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (pharmacology), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Pharmacological, Camptothecin (adverse effects), Camptothecin (analogs & derivatives), Camptothecin (pharmacology), Camptothecin (therapeutic use), Colorectal Neoplasms (pathology), Disease Progression, Disease-Free Survival, Female, Fluorouracil (adverse effects), Fluorouracil (pharmacology), Fluorouracil (therapeutic use), Humans, Leucovorin (adverse effects), Leucovorin (pharmacology), Leucovorin (therapeutic use), Male, Neoplasm Metastasis, Organoplatinum Compounds (therapeutic use), Proportional Hazards Models, Receptors, Vascular Endothelial Growth Factor (adverse effects), Receptors, Vascular Endothelial Growth Factor (pharmacology), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (adverse effects), Recombinant Fusion Proteins (therapeutic use).
- MESH :
- chemical , adverse effects : Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical , analogs & derivatives : Camptothecin.
- chemical , pharmacology : Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor.
- chemical , therapeutic use : Camptothecin, Fluorouracil, Leucovorin, Organoplatinum Compounds, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical : Biomarkers, Pharmacological.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- pathology : Colorectal Neoplasms.
- pharmacology : Antineoplastic Combined Chemotherapy Protocols.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Disease Progression, Disease-Free Survival, Female, Humans, Male, Neoplasm Metastasis, Proportional Hazards Models.
Abstract
Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.
DOI: 10.1016/j.ejca.2014.10.019
PubMed: 25466509
Links to Exploration step
pubmed:25466509Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.</title><author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name><affiliation><nlm:affiliation>University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name><affiliation><nlm:affiliation>Russells Hall Hospital, Dudley, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name><affiliation><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name><affiliation><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name><affiliation><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hoff, Paulo M" sort="Hoff, Paulo M" uniqKey="Hoff P" first="Paulo M" last="Hoff">Paulo M. Hoff</name><affiliation><nlm:affiliation>Centro De Oncologia/Hospital Sirio Libanes, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name><affiliation><nlm:affiliation>The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Arnold, Dirk" sort="Arnold, Dirk" uniqKey="Arnold D" first="Dirk" last="Arnold">Dirk Arnold</name><affiliation><nlm:affiliation>Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmoll, Hans J" sort="Schmoll, Hans J" uniqKey="Schmoll H" first="Hans J" last="Schmoll">Hans J. Schmoll</name><affiliation><nlm:affiliation>Martin Luther University Halle-Wittenberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name><affiliation><nlm:affiliation>Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation.</nlm:affiliation></affiliation></author><author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name><affiliation><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ten Tije, Albert J" sort="Ten Tije, Albert J" uniqKey="Ten Tije A" first="Albert J" last="Ten Tije">Albert J. Ten Tije</name><affiliation><nlm:affiliation>Amphia Hospital, Breda, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Vishwanath, Raghu L" sort="Vishwanath, Raghu L" uniqKey="Vishwanath R" first="Raghu L" last="Vishwanath">Raghu L. Vishwanath</name><affiliation><nlm:affiliation>Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Bhargava, Pankaj" sort="Bhargava, Pankaj" uniqKey="Bhargava P" first="Pankaj" last="Bhargava">Pankaj Bhargava</name><affiliation><nlm:affiliation>Sanofi Global Oncology Research and Development, Cambridge, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name><affiliation><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Macarulla, Teresa" sort="Macarulla, Teresa" uniqKey="Macarulla T" first="Teresa" last="Macarulla">Teresa Macarulla</name><affiliation><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25466509</idno><idno type="pmid">25466509</idno><idno type="doi">10.1016/j.ejca.2014.10.019</idno><idno type="wicri:Area/PubMed/Corpus">003185</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003185</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.</title><author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name><affiliation><nlm:affiliation>University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name><affiliation><nlm:affiliation>Russells Hall Hospital, Dudley, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name><affiliation><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name><affiliation><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name><affiliation><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hoff, Paulo M" sort="Hoff, Paulo M" uniqKey="Hoff P" first="Paulo M" last="Hoff">Paulo M. Hoff</name><affiliation><nlm:affiliation>Centro De Oncologia/Hospital Sirio Libanes, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name><affiliation><nlm:affiliation>The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Arnold, Dirk" sort="Arnold, Dirk" uniqKey="Arnold D" first="Dirk" last="Arnold">Dirk Arnold</name><affiliation><nlm:affiliation>Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmoll, Hans J" sort="Schmoll, Hans J" uniqKey="Schmoll H" first="Hans J" last="Schmoll">Hans J. Schmoll</name><affiliation><nlm:affiliation>Martin Luther University Halle-Wittenberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name><affiliation><nlm:affiliation>Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation.</nlm:affiliation></affiliation></author><author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name><affiliation><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ten Tije, Albert J" sort="Ten Tije, Albert J" uniqKey="Ten Tije A" first="Albert J" last="Ten Tije">Albert J. Ten Tije</name><affiliation><nlm:affiliation>Amphia Hospital, Breda, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Vishwanath, Raghu L" sort="Vishwanath, Raghu L" uniqKey="Vishwanath R" first="Raghu L" last="Vishwanath">Raghu L. Vishwanath</name><affiliation><nlm:affiliation>Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Bhargava, Pankaj" sort="Bhargava, Pankaj" uniqKey="Bhargava P" first="Pankaj" last="Bhargava">Pankaj Bhargava</name><affiliation><nlm:affiliation>Sanofi Global Oncology Research and Development, Cambridge, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name><affiliation><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Macarulla, Teresa" sort="Macarulla, Teresa" uniqKey="Macarulla T" first="Teresa" last="Macarulla">Teresa Macarulla</name><affiliation><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (pharmacology)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Pharmacological</term><term>Camptothecin (adverse effects)</term><term>Camptothecin (analogs & derivatives)</term><term>Camptothecin (pharmacology)</term><term>Camptothecin (therapeutic use)</term><term>Colorectal Neoplasms (pathology)</term><term>Disease Progression</term><term>Disease-Free Survival</term><term>Female</term><term>Fluorouracil (adverse effects)</term><term>Fluorouracil (pharmacology)</term><term>Fluorouracil (therapeutic use)</term><term>Humans</term><term>Leucovorin (adverse effects)</term><term>Leucovorin (pharmacology)</term><term>Leucovorin (therapeutic use)</term><term>Male</term><term>Neoplasm Metastasis</term><term>Organoplatinum Compounds (therapeutic use)</term><term>Proportional Hazards Models</term><term>Receptors, Vascular Endothelial Growth Factor (adverse effects)</term><term>Receptors, Vascular Endothelial Growth Factor (pharmacology)</term><term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term><term>Recombinant Fusion Proteins (adverse effects)</term><term>Recombinant Fusion Proteins (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Camptothecin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term><term>Receptors, Vascular Endothelial Growth Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term><term>Organoplatinum Compounds</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers, Pharmacological</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Neoplasm Metastasis</term><term>Proportional Hazards Models</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25466509</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>26</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.</ArticleTitle><Pagination><MedlinePgn>18-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2014.10.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(14)01055-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614). Hazard ratios (HR) by 6-month time period were estimated using a piecewise Cox proportional hazard model. Severity of adverse events (AEs) was graded using National Cancer Institute Common Terminology Criteria, version 3.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The estimated probabilities of survival were 38.5% versus 30.9% at 18 months, 28.0% versus 18.7% at 24 months and 22.3% versus 12.0% at 30 months, for the aflibercept- and placebo-treated arms, respectively. The proportional improvement in the HR over time was consistent with the survival probability results; survival at 24 months was improved by 50% and almost doubled at 30 months. The majority of worst-grade AEs occurred within the first four cycles of treatment and in a small percent of treatment cycles and were mostly reversible. Common chemotherapy- and anti-vascular epithelial growth factor (VEGF)-associated AEs occurred rarely and in a small proportion of cycles with the majority being of single occurrence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The addition of aflibercept to FOLFIRI showed a continued and persistent improvement in overall survival over time in patients with mCRC. Although grade 3-4 AEs were more frequent in the aflibercept arm, they occurred in early treatment cycles and decreased sharply following initial presentation.</AbstractText><CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferry</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Russells Hall Hospital, Dudley, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakomỳ</LastName><ForeName>Radek</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prausová</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hazel</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>University of Western Australia, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoff</LastName><ForeName>Paulo M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Centro De Oncologia/Hospital Sirio Libanes, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmoll</LastName><ForeName>Hans J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Martin Luther University Halle-Wittenberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moiseyenko</LastName><ForeName>Vladimir M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKendrick</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Monash University, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Tije</LastName><ForeName>Albert J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Amphia Hospital, Breda, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vishwanath</LastName><ForeName>Raghu L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhargava</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sanofi Global Oncology Research and Development, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>Soazig</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sanofi, Vitry-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macarulla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Cutsem</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Hospitals Leuven and KU Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054316">Biomarkers, Pharmacological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>04ZR38536J</RegistryNumber><NameOfSubstance UI="C030110">oxaliplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H43101T0J</RegistryNumber><NameOfSubstance UI="C051890">irinotecan</NameOfSubstance></Chemical><Chemical><RegistryNumber>15C2VL427D</RegistryNumber><NameOfSubstance UI="C533178">aflibercept</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>XT3Z54Z28A</RegistryNumber><NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054316" MajorTopicYN="N">Biomarkers, Pharmacological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aflibercept</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">PlGF</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">VEGF-A</Keyword><Keyword MajorTopicYN="N">VEGF-B</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25466509</ArticleId><ArticleId IdType="pii">S0959-8049(14)01055-7</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2014.10.019</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003185 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003185 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25466509
|texte= Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25466509" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |